Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia-Reference-Cited by-同舟云学术

Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia

Published:2017 Issue: Volume: Page:1-37
ISSN:1862-2461
Container-title:Topics in Medicinal Chemistry
language:
Short-container-title:

Author:

Manley Paul W.,Stiefl Nikolaus J.

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/7355_2017_5

Reference152 articles.

1. Manley PW, Holzer P, Möbitz H, Skaanderup PR, Stauffer F (2015) Progress into the era of genomically targeted cancer drugs: 50 years of anticancer medicinal chemistry. Med Chem Rev 50:185–203

2. Neumann E (1872) Ein neuer Fall von Leukamie mit Erkrankung des Knochenmarks. Archives Heilkunde 13:502–508

3. Höglund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(Suppl 2):241–247

4. Nowell PC (2007) Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 117:2033–2035

5. Hunter T (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest 117:2036–2043

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States;Journal of Health Economics and Outcomes Research;2022-08-04

2. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States;Journal of Health Economics and Outcomes Research;2022-08-04

3. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase;Leukemia Research;2020-11

4. A Chemical Approach to Overcome Tyrosine Kinase Inhibitors Resistance: Learning from Chronic Myeloid Leukemia;Current Medicinal Chemistry;2019-12-02

5. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1;Journal of Medicinal Chemistry;2018-08-23